TOG Review (RCOG Journal)
MRCOG Part 2
Maternal Medicine
Inflammatory bowel disease in pregnancy
Key Statistics
- 50% — IBD diagnosed before age 35
- 2× — RR active disease if active at conception
- 30% — Relapse risk in pregnancy if quiescent at conception
Don't-miss facts
-
Key predictors of good outcome: clinical remission at conception + good disease control in pregnancy
-
Active disease at conception → 2× RR of active disease in pregnancy; quiescent disease → ~30% relapse risk (same as non-pregnant)
-
UC (not CD): significantly ↑activity during pregnancy (RR 2.19) and postpartum (RR 6.22)
-
Methotrexate = contraindicated (FDA X); mycophenolate mofetil = avoid; stop ≥3 months pre-conception
-
Sulfasalazine: max 3 g/day; give 5 mg/day folic acid
-
Avoid CT in pregnancy; avoid fluoroquinolones; avoid anti-integrins (vedolizumab) where possible
-
Biologics: discontinue by 30–32 weeks; delay live vaccines in exposed infants until drug undetectable (≥6 months)
-
Steroids >5 mg prednisolone-equivalent for >4 weeks pre-delivery → hydrocortisone cover at delivery/labour
-
Avoid episiotomy (perianal disease trigger); planned caesarean for active perianal/rectal disease or post ileo-anal pouch surgery
-
Postpartum: NSAIDs may worsen IBD; opiates → constipation/worsened perianal disease – co-prescribe osmotic laxatives
Drug safety at a glance
Continue: aminosalicylates, metronidazole, steroids, thiopurines, biologics
Avoid/stop: methotrexate, mycophenolate mofetil, anti-integrins (preferably), fluoroquinolones
Abbreviation Key
- IBD — inflammatory bowel disease
- MRI — magnetic resonance imaging
- CD — Crohn’s disease
- CT — computed tomography
- UC — ulcerative colitis
- ECCO — European Crohn’s and Colitis Organisation
- NICE — National Institute for Health and Care Excellence
- TREAT — Therapy Resource Evaluation Assessment Tool registry
- FDA — US Food and Drug Administration
- PIANO — Pregnancy in IBD and Neonatal Outcomes registry
- TNF — tumour necrosis factor
- GETAID — Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif
- IL — interleukin
- Fc — fragment crystallisable (placental IgG transfer receptor)
Source: Kapoor A et al. Inflammatory bowel disease in pregnancy. The Obstetrician & Gynaecologist 2016;18:205–212. doi:10.1111/tog.12271
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).